Furthermore, although we used guanfacine, a Food and Drug Administration (FDA)–approved agent known to reduce stress‐triggered drug craving in humans,57 to diminish the effects of depression vulnerability on secondary AUD, we did not examine the effects of putative antidepressant treatment against the comorbid phenotype. Future studies should address whether antidepressants can ameliorate AUD‐like behaviors after SDPS and whether depression proneness determines the efficacy of such agents.
